BIOSENSORS Strategic Roadmap FY 20092010

1
The abluminal biodegradable polymer DES
2
BioMatrix The abluminal biodegradable polymer
DES
BIODEGRADABLE PLA PLA biodegradation along with
BA9 elution No PLA /BA9 coating on the stent
after 6 to 9months
S-STENT PLATFORM High flexibility without
compromising vessel support Unmatched side branch
access
Data on file molecular weightlt10kDa
3
S-STENT PLATFORM
UNMATCHED SIDE BRANCH ACCESS Optimized cell
design providing largest cell diameter
HIGH FLEXIBILITY VESSEL SUPPORT Unique
Quadrature Link connectors Different models for
small and large vessels
IIB 27/2006 Data on file
4
BIOLIMUS A9 DRUG
PROPRIETARY DRUG BA9 A rapamycin derivative
developed specifically for stent application by
Biosensors Reduced systemic exposure and more
localized drug effect due to highest lipophilic
profile and abluminal coating Effective
immunosuppressive and anti-proliferative
properties
LIPOPHILICITY COMPARISON Highest lipophilic and
hydrophobic properties of commercially available
limus drugs Minimizes attraction to blood and
maximizes tissue absorption Minimizing drug
release into bloodstream
/- 2.8 (valid for all drugs tested)
5
ABLUMINAL BIODEGRADABLE COATING
PLA biodegradation along with BA9 elution No
PLA /BA9 coating on the stent after 6 to
9months Abluminal coating reduces total amount
of polymer used High drug carrying capacity of
PLA allowing for lower amount of polymer
6
BioMatrix The Abluminal Biodegradable Polymer
DES
No PLA /BA9 coating on the stent after 6 to 9
months
Biodegradation of PLA Elution of BA9
7
Rue de Lausanne 29 1110 MORGES
Switzerland Tel. [phone] Fax (41)
0 21 804 80 01 customer_at_biosensors.com